Skip to content

Effect of esketamine on postoperative pain and early cognitive function in elderly patients undergoing thoracic surgery

Effect of esketamine on postoperative pain and early cognitive function in elderly patients undergoing thoracic surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065266
Enrollment
Unknown
Registered
2022-11-01
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

elderly patients undergoing thoracic surgery

Interventions

Esketamine group:Propofol 2-4mg/kg/h and esketamine 0.3mg/kg/h were administered with intermittent bolus atracurium
control group:Anesthesia was maintained with propofol at 2-4mg/kg/h and remifentanil at 0.1-0.2µg/kg/min, with intermittent bolus atracurium and sufentanil.

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 75 Years

Inclusion criteria

Inclusion criteria: ASAI-II grade, 65-75 years old, with preoperative diagnosis of lung tumor requiring thoracoscopic single lobectomy and lymph node dissection. Patients had no cognitive impairment (MMSE>24) before the test and had not received anesthesia or surgery in the past 6 months.

Exclusion criteria

Exclusion criteria: 1) suffering from mental illness; 2) organic heart disease, hypertension and arrhythmia; 3) severe liver and kidney diseases; 4) intracranial mass, intracranial aneurysm, intracranial hemorrhage or organic brain damage in the past six months; 5) glaucoma, high intraocular pressure and retinal detachment; 6) difficult ventilation or intubation; 7) severe cognitive impairment before surgery; 8) previous allergy to anesthetic drugs; 9) previous drug or alcohol addicts; 10) those who refused to participate in the experiment; 11) those with low education level could not understand the content of the questionnaire 12) have participated in other clinical trials

Design outcomes

Primary

MeasureTime frame
Mini-mental State Examination;

Secondary

MeasureTime frame
vital signs;adverse event rate;

Countries

china

Contacts

Public ContactLeng Zhou

West China Hospital of Sichuan University

zhoulenghx@foxmail.com+86 18980601585

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026